{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:44:45Z","timestamp":1780415085517,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"HePAtological TOXicity of Drugs","award":["NCT03833297"],"award-info":[{"award-number":["NCT03833297"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.autrev.2020.102460","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T06:13:18Z","timestamp":1578377598000},"page":"102460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Characterization of auto-immune hepatitis associated with the use of anti-TNF\u03b1 agents: An analysis of 389 cases in VigiBase"],"prefix":"10.1016","volume":"19","author":[{"given":"Olivier","family":"Vollmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102460_bb0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102460_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2018.06.016","article-title":"Liver-associated immune abnormalities","volume":"18","author":"Grunebaum","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102460_bb0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","article-title":"International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement","volume":"16","author":"Zignego","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102460_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2017.01.015","article-title":"Autoimmune hepatitis and occult HCV infection: a prospective single-centre clinical study","volume":"16","author":"Dvir","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102460_bb0030","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis--Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0035","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"L. European Association for the Study of the","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0040","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bjornsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","author":"e.e.e. European Association for the Study of the Liver","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0055","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102460_bb0060","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2020.102460_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102460_bb0070","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","article-title":"Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102460_bb0075","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102460_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40264-015-0366-9","article-title":"Hepatotoxicity associated with the use of anti-TNF-alpha agents","volume":"39","author":"French","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2020.102460_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102460_bb0090","first-page":"633","article-title":"Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes","volume":"9","author":"Guy","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.autrev.2020.102460_bb0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","article-title":"Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab","volume":"26","author":"Garcia Aparicio","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","article-title":"Infliximab-induced hepatitis: absence of cross-toxicity with etanercept","volume":"75","author":"Thiefin","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2020.102460_bb0105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/BOR.0b013e32832f13db","article-title":"Drug-induced autoimmunity","volume":"21","author":"Dedeoglu","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102460_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1196\/annals.1423.034","article-title":"Autoantibody production in anti-TNF-alpha-treated patients","volume":"1110","author":"Alessandri","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2020.102460_bb0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2020.102460_bb0120","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/hep.23870","article-title":"Anti-tumor necrosis factor alpha treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C","volume":"52","author":"Brenndorfer","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2020.102460_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:03Z","timestamp":1761599883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1568997220300033"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102460","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of auto-immune hepatitis associated with the use of anti-TNF\u03b1 agents: An analysis of 389 cases in VigiBase","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102460"}}